---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-025432"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2026-03-10T23:59:59+00:00"
generated_at: "2026-05-15T15:46:24.582058+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Protara Therapeutics Q4 net loss $17.3M; TARA-002 shows 68% CR in BCG-Unresponsive NMIBC

## Summary
- Net loss Q4 2025: $17.3M ($0.37/share); FY2025: $57.4M ($1.34/share).
- Cash $197.9M as of Dec 31, 2025; expects funding into 2028 after $86.3M December offering.
- TARA-002 in BCG-Unresponsive NMIBC: 68.2% complete response at six months; no grade 3+ TRAEs.
- FDA granted TARA-002 Breakthrough Therapy and Fast Track designations for lymphatic malformations.
- Expects to complete BCG-Unresponsive cohort enrollment in 2H 2026; initiate ADVANCED-3 trial in 2H 2026.

## SEC filing metadata
- accession: 0001213900-26-025432
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2026-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/0001213900-26-025432-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/ea0280404-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-025432
- JSON: https://secwatch.observer/filing/0001213900-26-025432.json
- Plain text: https://secwatch.observer/filing/0001213900-26-025432.txt

## Key facts
- Earnings Releases
  Protara Therapeutics, Inc. reported financial results for the fourth quarter of 2025.
  - Period: the fourth quarter of 2025
  - Result: reported results
  source text: Research and development expenses for the fourth quarter of 2025 increased to $13.1 million from $9.5 million for the prior year period
  evidence_url: https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/0001213900-26-025432-index.htm
- Earnings Releases
  Protara Therapeutics, Inc. reported financial results for the full year ended December 31, 2025.
  - Period: the full year ended December 31, 2025
  - Result: reported results
  source text: and for the full year increased to $42.6 million compared to $31.7 million for 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/0001213900-26-025432-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.